摘要
Abstract
Objective To study the effect of moxifloxacin on dyspnea and pulmonary function in patients with acute exacerbation of mild to moderate chronic obstructive pulmonary disease(COPD).Methods This study included 69 patients meeting the criteria for acute exacerbation of mild to moderate COPD from our hospital during the period of January to September 2024.Patients were randomized via a random number table,34 patients assigned to the routine group,which were received piperacillin sodium and tazobactam sodium for injection,while the remaining 35 patients in the study group were treated with moxifloxacin hydrochloride and sodium chloride injection.The clinical efficacy,degree of dyspnea(mMRC score),pulmonary function indexes(FVC,FEV1),inflammatory indexes(WBC,CRP),and incidence of adverse reactions(gastrointestinal symptoms,headache,rash)were compared between the two groups.Results The study group demonstrated a significantly higher total treatment effective rate(94.29%)compared to the routine group(85.29%)(P<0.05).After treatment,the degree of dyspnea(mMRC score),pulmonary function indexes(FVC,FEV1)and inflammatory indexes(WBC,CRP)in the two groups were improved compared with those before treatment,with outcomes in the study group being superior to those in the routine group(P<0.05).The study group demonstrated a significantly lower incidence of adverse reactions(5.71%)compared with the conventional group(14.71%)(P<0.05).Conclusion Moxifloxacin is effective in the treatment of patients with mild to moderate acute exacerbation of COPD.It has a positive effect in reducing the degree of dyspnea,improving pulmonary function,inhibiting inflammatory response and reducing the incidence of adverse reactions.关键词
莫西沙星/慢性阻塞性肺疾病/急性加重期/肺功能Key words
Moxifloxacin/Chronic obstructive pulmonary disease/Acute exacerbation/Pulmonary function分类
医药卫生
